Orbimed Advisors LLC Raises Stake in Bicara Therapeutics Inc. (NASDAQ:BCAX)

Orbimed Advisors LLC raised its holdings in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) by 9.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 298,301 shares of the company's stock after acquiring an additional 26,391 shares during the quarter. Orbimed Advisors LLC owned 0.55% of Bicara Therapeutics worth $5,196,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Spire Wealth Management acquired a new position in shares of Bicara Therapeutics during the 4th quarter worth $31,000. BNP Paribas Financial Markets acquired a new position in shares of Bicara Therapeutics during the 4th quarter worth $32,000. Legal & General Group Plc acquired a new position in shares of Bicara Therapeutics during the 4th quarter worth $33,000. Summit Investment Advisors Inc. acquired a new position in shares of Bicara Therapeutics during the 4th quarter worth $35,000. Finally, Virtus ETF Advisers LLC acquired a new position in shares of Bicara Therapeutics during the 4th quarter worth $69,000.

Bicara Therapeutics Price Performance

BCAX remained flat at $14.47 during midday trading on Friday. The company's stock had a trading volume of 594,520 shares, compared to its average volume of 488,219. The firm has a 50-day simple moving average of $12.81 and a 200-day simple moving average of $15.25. Bicara Therapeutics Inc. has a 52 week low of $8.91 and a 52 week high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.28). Equities research analysts anticipate that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on BCAX. Wells Fargo & Company began coverage on Bicara Therapeutics in a research note on Thursday, April 17th. They set an "underweight" rating and a $8.00 price target for the company. Stifel Nicolaus set a $48.00 target price on shares of Bicara Therapeutics in a research note on Thursday, March 27th. Wedbush reissued an "outperform" rating and issued a $31.00 target price on shares of Bicara Therapeutics in a research note on Thursday, March 27th. HC Wainwright cut their target price on shares of Bicara Therapeutics from $44.00 to $41.00 and set a "buy" rating for the company in a research note on Friday. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $13.01 target price on shares of Bicara Therapeutics in a research note on Thursday, March 13th. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $32.00.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.